Postoperative Radiation Therapy Is Indicated for “Low-Risk” Pathologic Stage I Merkel Cell Carcinoma of the Head and Neck Region but Not for Other Locations

Bierma, M. M., Goff, P. H., Hippe, D. S., Lachance, K., Schaub, S. K., Wallner, K., Tseng, Y. D., Liao, J. J., Apisarnthanarax, S., Nghiem, P., & Parvathaneni, U

Advances in radiation oncology, 9(2), 101364. https://doi.org/10.1016/j.adro.2023.101364

PMID: 38189056

View on PubMed -

Purpose: The role of postoperative radiation therapy (PORT) in early stage Merkel cell carcinoma (MCC) is controversial. We analyzed the role of PORT in preventing local recurrences (LR) among patients with low-risk, pathologic stage I MCC based on the location of the primary tumors: head/neck (HN) versus non-HN sites.

Methods and materials: One hundred forty-seven patients with MCC were identified that had “low risk” disease (pathologic T1 primary tumor, negative microscopic margins, negative pathologic node status, no immunosuppression or prior systemic therapy). LR was defined as tumor recurrence within 2 cm of the primary surgical bed, and its frequency was estimated with the cumulative incidence method.

Results: Seventy-nine patients received PORT (30 HN, 49 non-HN) with a median dose of 50 Gy (range, 8-64 Gy) and 68 patients were treated with surgery alone (30 HN, 38 non-HN). Overall, PORT was associated with a decreased risk of LR (5-year rate: 0% vs 9.5%; P = .004) with 6 LRs observed in the surgery alone group. Although the addition of PORT significantly reduced LR rates among patients with HN MCC (0% vs. 21%; P = .034), no LRs were observed in patients with non-HN MCC managed with surgery alone. There was no significant difference in MCC-specific survival comparing HN versus non-HN groups, with or without PORT.

Conclusions: For low-risk, pathologic stage I MCC of the extremities and trunk, excellent local control rates were achieved with surgery, and PORT is not indicated. However, PORT was associated with a significant reduction in LRs among low-risk MCC of the HN.

Advances in radiation oncology, 9(2), 101364. https://doi.org/10.1016/j.adro.2023.101364